Crossmark

Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Crossref DOI link: https://doi.org/10.1007/s00134-018-5390-7

Published Online: 2018-09-28

Published Print: 2018-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bassetti, Matteo https://orcid.org/0000-0002-4406-962X
Akova, Mura

Tumbarello, Mario
License Information

Text and Data Mining valid from 2018-09-28
More Information

Article History

Received: 22 September 2018

Accepted: 24 September 2018

First Online: 28 September 2018

Change Date: 9 November 2018

Change Type: Correction

Change Details: The original version of this article unfortunately contained a mistake.

Compliance with ethical standards

:

: Dr. Bassetti has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Bayer, Basilea, Gilead, Menarini, MSD, Pfizer, The Medicine Company, Tetraphase and Vifor. Dr. Akova has no conflict of interests. Dr. Tumbarello has participated in advisory boards and/or received speaker honoraria from Achaogen, Angelini, Astellas, AstraZeneca, Gilead, MSD, Nordic Pharma and Pfizer.